PI
CRNX icon

PEAK6 Investments’s Crinetics Pharmaceuticals CRNX Stock Holding History

PEAK6 Investments’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$511K Buy
10,000
+2,000
+25% +$103K ﹤0.01% 2301
2024
Q2 		$358K Buy
+8,000
New +$369K ﹤0.01% 2433

Other funds holding CRNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

PEAK6 Investments's CRNX Position: Q3 2024 in Review

PEAK6 Investments increased its Crinetics Pharmaceuticals (CRNX) stake by 25% in Q3 2024, buying an estimated $103K and bringing the position to 10,000 shares worth $511K. The position accounts for ﹤0.01% of the portfolio, ranked #2301.

PEAK6 Investments first reported a position in CRNX in Q2 2024 and has held it in 2 quarters since. 235 funds tracked by Wall St. Rank hold CRNX as of Q3 2024.

  • PEAK6 Investments held 10,000 shares of Crinetics Pharmaceuticals worth $511K as of Q3 2024.
  • PEAK6 Investments bought 2,000 Crinetics Pharmaceuticals shares in Q3 2024, an estimated $103K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of PEAK6 Investments's portfolio in Q3 2024, its #2301 holding.
  • PEAK6 Investments first reported a position in Crinetics Pharmaceuticals in Q2 2024 and has held it in 2 quarters since.
  • 235 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q3 2024.

Based on PEAK6 Investments's 13F filing for Q3 2024, filed 14 Nov 2024.